medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number 2

<< Back Next >>

Ann Hepatol 2006; 5 (2)

Clinical and virological features of acute HBV-related hepatitis in southern Vietnam

Thi NYen-Xuan, Tran PDieu-Hien, Ngoc CN, Saveria CL

Language: English
References: 28
Page: 92-96
PDF size: 80.19 Kb.


Text Extraction

Background: Despite the availability of effective vaccines, hepatitis B virus (HBV) infection is still frequent worldwide, and accounts for significant morbidity and mortality. However, data of acute HBeAg negative hepatitis still remain limited. Aims and Methods: To understand clinical pictures of acute HBV hepatitis and its natural evolution, a prospective study was conducted in adult patients. Results: Ninety patients were enrolled between March 2004 and April 2005 at Hospital for Tropical Diseases in Ho Chi Minh city. The prevalence of HBeAg negative was 53%. No significant difference was found in clinical characteristics and laboratory findings between HBeAg positive and negative patients. HBV-DNA was detected in 75% and 88% HBe negative and positive patients, respectively, where the frequency of ALT below 400 U/L was significantly higher in HBeAg negative cases (p = 0.01). Six month follow-up was available in 47 patients. HBsAg positivity was found in 16% of HBeAg negative subjects but only in 4.5% of HBeAg positive cases. Thirty two patients had neither HBsAg nor anti-HBs. Conclusions: The clinical and laboratory feature and the out-come at 6 months of HBV acute hepatitis in Vietnam is similar in HBeAg positive and negative patients.


REFERENCES

  1. World Health Organization. Hepatitis B. Revised October 2000. Last accessed January 2006. ed. http://www.who.int/mediacentre/factsheets/fs204/en/..

  2. Hipgrave DB, Nguyen TV, Vu MH, Hoang TL, Do TD, Tran NT, et al. Hepatitis B infection in rural Vietnam and the implications for a national program of infant immunization. Am J Trop Med Hyg 2003; 69(3): 288-294.

  3. Huy TT, Ushijima H, Quang VX, Ngoc TT, Hayashi S, Sata T, et al. Characteristics of core promoter and precore stop codon mutants of hepatitis B virus in Vietnam. J Med Virol 2004; 74(2): 228-236.

  4. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Crax A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126(1): 102-110.

  5. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1,536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135(9): 759-768.

  6. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2(8663): 588-591.

  7. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68(12): 8102-8110.

  8. Brunetto MR, Stemler M, Shodel F, Will H, Ottobrelli A, Rizzetto M, et al. Identification of HBV variants with cannot produce precore derived HBeAg and may be responsible for severe hepatitis. ed. 1989; 21: 151-154.

  9. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992; 89(1): 87-96.

  10. Chu CM, Liaw YF. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 1987; 92(1): 220-225.

  11. Chang C, Enders G, Sprengel R, Peters N, Varmus HE, Ganem D. Expression of the precore region of an avian hepatitis B virus is not required for viral replication. J Virol 1987; 61(10): 3322-3325.

  12. Gowans EJ. Relationship between HBeAg and HBV DNA in patients with acute and persistent hepatitis B infection. Med J Aust 1986; 145(9): 439-441.

  13. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41(4): 771-778.

  14. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174(6): 1565-1570.

  15. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324(24): 1699-1704.

  16. Lee WM. Acute liver failure. N Engl J Med 1993; 329(25): 1862-1872.

  17. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23(1): 47-58.

  18. Fattovich G. Natural history of hepatitis B. J Hepatol 2003; 39 Suppl 1: S50-S58.

  19. Krogsgaard K, Kryger P, Aldershvile J, Andersson P, Brechot C. Hepatitis B virus DNA in serum from patients with acute hepatitis B. Hepatology 1985; 5(1): 10-13.

  20. Woolf IL, El Sheikh N, Cullens H, Eddleston AL, Williams R. HBeAg in viral hepatitis type B. Digestion 1978; 17(4): 317-322.

  21. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337(24): 1733-1745.

  22. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004; 350(11): 1118-1129.

  23. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006; 43(2 Suppl 1): S173-S181.

  24. Bonino F, Hoyer B, Nelson J, Engle R, Verme G, Gerin J. Hepatitis B virus DNA in the sera of HBsAg carriers; a marker of active Hepatitis B virus replication in the liver. ed. 1981; 1: 386-391.

  25. Gimson AE, Tedder RS, White YS, Eddleston AL, Williams R. Serological markers in fulminant hepatitis B. Gut 1983; 24(7): 615-617.

  26. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002; 122(1): 244-245.

  27. Lange WR, Moore JD, Cibull ML, Brutsche RL. Human immunodeficiency virus as a possible cofactor in the development of fulminant hepatitis B in intravenous drug abusers. J Med 1988; 19(3-4): 203-214.

  28. Fay O, Tanno H, Roncoroni M, Edwards VM, Mosley JW, Redeker AG. Prognostic implications of the e antigen of hepatitis B virus. JAMA 1977; 238(23): 2501-2503.




2020     |     www.medigraphic.com